Evidence map›Paper›PMID 31275607›Full record

Trial reportRMD open2019

Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients.

Laure Gossec, Martin Soubrier, Frantz Foissac, Anna Molto, Pascal Richette, Catherine Beauvais, Adeline Ruyssen-Witrand, Aleth Perdriger, Isabelle Chary-Valckenaere, Gael Mouterde and 12 more

Registry-linked trialOpen access · goldAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in RMD open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01315652 (Evaluation of the Usefulness of a Center Specialized in the Standardized Management of Rheumatoid Arthritis), which is not on this map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01315652 nacompletednot on this map

Evaluation of the Usefulness of a Center Specialized in the Standardized Management of Rheumatoid Arthritis: The COMEDRA Trial

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2011 to 2016Enrolled970ConditionsRheumatoid ArthritisArmsComorbidities treatment, Auto-DAS
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Management strategies in rheumatoid arthritis.Nature reviews. Rheumatology · 2024
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 16 institutions in 1 country.

Laure GossecSorbonne Universite, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Paris, France.ORCID 0000-0002-4528-310X
Martin SoubrierRheumatology, Gabriel Montpied University Hospital, Clermont-Ferrand, France.ORCID 0000-0001-9349-0720
Frantz FoissacClinical Research Unit Necker-Cochin, Assistance Publique-Hopitaux de Paris, Paris, Île-de-France, France.
Anna MoltoRheumatology, Cochin Hospital, AP-HP, Paris, France.ORCID 0000-0003-2246-1986
Pascal RichetteRheumatology, Lariboisiere Hospital AP-HP, Paris, France.ORCID 0000-0003-2132-4074
Catherine BeauvaisRheumatology, Sorbonne Université and Hopital Saint-Antoine AP-HP, Paris, France.
Adeline Ruyssen-WitrandRheumatology, UMR 1027 Inserm, Paul Sabatier University and Purpan Hospital, Toulouse, France.
Aleth PerdrigerRheumatology, South Hospital, Rennes 1 University, Rennes, France.
Isabelle Chary-ValckenaereRheumatology, Nancy University Hospital, Vandoeuvre les Nancy, France.
Gael MouterdeImmuno-rhumatologie, Lapeyronie Hospital and Montpellier University, Montpellier, France.
Emanuelle DernisRheumatology, Le Mans Hospital, Le Mans, France.
Liana Euller-ZieglerRheumatology, University Hospital Pasteur 2, Nice, France.
René-Marc FlipoRheumatology, R Salengro Hospital, University of Lille, Lille, France.
Mélanie GilsonRheumatology, GREPI-CNRS, Grenoble Hospital and Université Joseph Fourier, Echirolles, France.
Sandrine GuisRheumatology, University Hospital, AP-HM, Marseille, France.
Xavier MarietteRheumatology, HôpitauxUniversitaires Paris-Sud, Université Paris-Sud, INSERM UMR1184, Le Kremlin Bicetre, France.
Sophie PouplinRheumatology, Rouen University Hospital, Rouen, France.
Thierry MarhadourRheumatology, Cavale Blanche Hospital and INSERM 1227, Université Bretagne Occidentale, Brest, France.
Thierry SchaeverbekeRheumatology, Pellegrin Hospital, Bordeaux University, CNRS 5164, Bordeaux, France.
Christelle SordetRheumatology, Hautepierre Hospital, Fédération de médecine translationnelle, UMR INSERM 1109, Strasbourg, France.
Françoise FayetRheumatology, Gabriel Montpied University Hospital, Clermont-Ferrand, France.
Maxime DougadosRheumatology, Cochin Hospital, AP-HP, Paris, France.
Inserm · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRCentre National de la Recherche Scientifique · FRDélégation Paris 5 · FRAssistance Publique Hôpitaux de Marseille · FRCentre Hospitalier du Mans · FRCentre Hospitalier Régional et Universitaire de Nancy · FRCentre Hospitalier Universitaire de Rouen · FRHôpital Cochin · FRHôpital Pasteur · FRSorbonne Université · FRUniversité de Lille · FRUniversité de Montpellier · FRUniversité Paris-Sud · FRUniversité Rennes 2 · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/purpose: Cardiovascular (CV) risk, cancer, infections and osteoporosis should be screened for in rheumatoid arthritis (RA). The objective was to assess 3-year effects of a nurse visit for comorbidity counselling. Methods: This was an open long-term (3 years) extension of the Comorbidities and Education in Rheumatoid Arthritis 6-month randomised controlled trial in which patients with definite, stable RA were visiting a nurse for comorbidity counselling. Comorbidity status was assessed and nurses provided advice on screening and management, at baseline and 3 years later. A score was developed to quantify comorbidity screening and management: 0-100, where lower scores indicate better screening and management. The score was compared between baseline and 3-year assessment using a Wilcoxon test for paired data. Results: Of the 970 recruited patients, 776 (80%) were followed-up at 2-4 years and 769 (79%) had available data for comorbidities at both time points: mean (±SD) age 58 (±11) years and mean disease duration 14 (±10) years; 614 (80%) were women, the mean Disease Activity Score 28 was 3.0±1.3, and 538 (70%) were receiving a biologic. At baseline, the mean comorbidity screening score was 36.6 (±19.9) and it improved at 3 years to 24.3 (±17.8) (p<0.0001), thus with a relative improvement of 33% (improvement of 12 points). CV risk screening, vaccination status and bone densitometry performance improved the most. Conclusions: Comorbidity screening was suboptimal but improved notably over 3 years, after a nurse-led programme aiming at checking systematically for comorbidity screening and giving patient advice. This long-term efficacy pleads in favour of nurse-led interventions to better address comorbidities in RA. Trial registration number: NCT01315652.

Indexed as

AgedArthritis, RheumatoidCardiovascular DiseasesComorbidityDelivery of Health CareFemaleHumansLongitudinal StudiesMaleMass ScreeningMiddle AgedNeoplasmsNurses, Community HealthOsteoporosisPatient Education as TopicProspective Studiescardiovascular diseasemultidisciplinary team carenursingrheumatoid arthritisvaccination

Identifiers

PMID31275607
PMCPMC6579559
OpenAlexW2949825809

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.